Before starting TB-500, the three things that matter most are: confirming the injury type is one with supporting preclinical data, using a conservative loading dose rather than starting at maintenance, and understanding that human trial evidence for musculoskeletal applications does not yet exist — outcomes are extrapolated from animal research.
Which injury types have the most supporting data for TB-500?
Preclinical data is strongest for soft tissue injuries — muscle, tendon, and ligament — and for cardiac tissue repair. Bone fracture data is thinner. If you are considering TB-500 for a soft tissue injury that has not responded to conventional treatment, you are working with the most supported use case. For other applications, the evidence base is considerably weaker.
What is the difference between loading and maintenance dosing?
TB-500 protocols typically use a loading phase (higher frequency, often 2–2.5mg twice weekly for 4–6 weeks) followed by a maintenance phase (once weekly or biweekly). Starting with loading rather than jumping to maintenance dose is conventional — it establishes tissue saturation faster in an acute injury context. Starting at maintenance dose for a chronic injury is also reasonable and reduces total compound exposure.